Intended for healthcare professionals

Rapid response to:

Practice Guidelines

Management of hypertension: summary of NICE guidance

BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d4891 (Published 25 August 2011) Cite this as: BMJ 2011;343:d4891

Rapid Response:

Re: Management of hypertension: summary of NICE guidance

In reponse to Kate Harding.

Choice of Antihypertensive Drug for Use in Pregnancy:

The Food and Drug Administration reviews human and animal data to assign letter grades corresponding with risk of fetal exposure in pregnancy. Most antihypertensive agents used in pregnancy are designated as “category C,” which states that human studies are lacking, animal studies are either positive for fetal risk or are lacking, and the drug should be given only if potential benefits justify potential risks to the fetus.1

Only small number of currently available drugs have been evaluated in pregnant women adequately and many others are contraindicated.

Reference:

1. Lindheimer MD, Barron WM. Medical Disorders in Pregnancy, 3rd ed. St. Louis: Mosby; 2000.

Competing interests: No competing interests

16 July 2012
Neeru Gupta
Scientist E
KK Jani
Indian Council of Medical Research
Ansari Nagar, New Delhi-110029